Any Fixed Combination Therapy

PreclinicalSmall molecule

Any Fixed Combination Therapy is one of 17 small molecule programs targeting Ocular Hypertension. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ocular HypertensionActive, not recruiting

Ocular HypertensionPreclinical

Active, not recruiting

Competition

Competitive Landscape

187 competitors in Ocular Hypertension

#DrugCompanyPhaseTrials

Alphagan

Novartis

Phase 3

1 2

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

9 3

Azopt

Novartis

Phase 3

1 4

Bimatoprost/timolol

AbbVie

Phase 3

4 5

Preservative-Free Tafluprost

Merck & Co.

Phase 3

2 6

Reference - LUMIGAN

AAmneal Pharmaceuticals, LLC

Phase 3

1 7

Combigan

EEMS

Phase 3

1 8

PRO-122

LLaboratorios Sophia S.A de C.V.

Phase 3

1 9

BOL-303259-X

BBausch & Lomb Incorporated

Phase 3

4 10

OPC-1085EL

Otsuka

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ocular Hypertension1 trial

A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Were Insufficiently Responsive to Monotherapy

Completed· AbbVie logo

AbbVie··NCT01637246·4,385 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Any Fixed Combination Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Any Fixed Combination Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Any Fixed Combination Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AbbVie

Any Fixed Combination Therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ocular Hypertension1 trial

References

Drug Info

Quick Facts

Related News